Therapy News and Research

RSS

Taste receptors in lungs can revolutionize treatment option for asthma

Taste receptors in the lungs. Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the receptors could revolutionize the treatment of asthma and other obstructive lung diseases.

25 Oct 2010

Botox beneficial for cosmetic dental treatment

A significant majority of dental implant patients are older with facial aging and their dentists may need to consider the benefits of rejuvenation techniques, such as Botox, for maximizing the cosmetic outcomes of the procedure, according to a leading cosmetic surgeon speaking at the American Academy of Implant Dentistry annual meeting.

25 Oct 2010

WallFlex Biliary RX Stent receives CE Mark approval for benign biliary strictures

Boston Scientific Corporation today announced that its WallFlex Biliary RX Fully Covered Stent has received CE Mark approval for the treatment of benign biliary strictures.

25 Oct 2010

GE Healthcare signs definitive agreement to acquire Clarient

GE Healthcare, a unit of General Electric Company and Clarient, Inc. announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the fast-growing molecular diagnostics sector.

25 Oct 2010

$Cedars-Sinai to develop world's first biological treatment for compression fractures$

Cedars-Sinai to develop world's first biological treatment for compression fractures

A team of physicians and scientists from the Cedars-Sinai Regenerative Medicine Institute and Department of Surgery, led by Dan Gazit, DMD, PhD has been awarded a three-year $1.9 million grant from the California stem cell agency to fund research leading to clinical trials for what could become the first biological treatment for the most common type of bone fracture in osteoporosis patients.

25 Oct 2010

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.

25 Oct 2010

Study on H1N1 virus to be presented at IDSA annual meeting

The 2009/2010 Influenza A (H1N1) is one of several viruses responsible for respiratory-related infections. A new study from Rhode Island Hospital examined patients with viruses and found distinguishing characteristics of the H1N1 virus in how it affects respiratory illness. Their findings will be presented at the annual meeting of the Infectious Diseases Society of America to be held in Vancouver, Canada on Friday, Oct. 22.

25 Oct 2010

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

UCSF scientists have received two grants from the California Institutefor Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure. The goal of the grants is for researchers to make significant strides toward the development of potential therapies within the next three years.

25 Oct 2010

Medivir reports consolidated net sales of SEK 54.7M

Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.

22 Oct 2010

Diamyd Medical to divide operations into two business areas

In her comments in today's year end report, Elisabeth Lindner, President and CEO of Diamyd Medical, states that the company has decided to divide its operations into two business areas beginning with the new 2010/2011 fiscal year; Diabetes and Pain.

22 Oct 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

AACR to host special conference on colorectal cancer

The American Association for Cancer Research will hosts its first special conference on Colorectal Cancer: Biology to Therapy from Oct. 27-30, 2010, at the Loews Hotel, Philadelphia.

22 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.

22 Oct 2010

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).

22 Oct 2010

Antigene therapy uses light energy to silence gene activity: Review article

Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity.

22 Oct 2010

New guidelines feature various key updates for stroke or TIA survivors

Treating metabolic syndrome and undergoing carotid angioplasty may prevent recurrent stroke or transient ischemic attack, according to revised American Heart Association/American Stroke Association guidelines.

22 Oct 2010

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

22 Oct 2010

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23, presentation number LB-38.

22 Oct 2010

New microchip separates tumour cells in blood stream

Ikerlan-IK4 and Mondragón Unibertsitatea are taking part in a project initiated by the Spanish National Research Council, CSIC, and which has developed a microchip capable of separating and extracting tumour cells in the blood stream by means of ultrasonic waves. The Foundation General Hospital of the University of Elche, together with researcher Alfredo Carrato, has also collaborated on this project.

22 Oct 2010

Therapy News and Research

Taste receptors in lungs can revolutionize treatment option for asthma

Botox beneficial for cosmetic dental treatment

WallFlex Biliary RX Stent receives CE Mark approval for benign biliary strictures

GE Healthcare signs definitive agreement to acquire Clarient

Cedars-Sinai to develop world's first biological treatment for compression fractures

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Study on H1N1 virus to be presented at IDSA annual meeting

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

Medivir reports consolidated net sales of SEK 54.7M

Diamyd Medical to divide operations into two business areas

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

AACR to host special conference on colorectal cancer

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Antigene therapy uses light energy to silence gene activity: Review article

New guidelines feature various key updates for stroke or TIA survivors

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

New microchip separates tumour cells in blood stream

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News